Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker TEVA
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Mark Sabag Officer, EXECUTIVE VP INTERNATIONAL MAR… | TEVA Teva Pharmaceutical Industries Limited | 44,710 | $2.0M | — | Nov 12, 2026 | Form 4 ↗ same day · 44,710 shares | Form 144 ↗ |
| Nov 12, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 20,003 | $856.2K | — | Nov 11, 2026 | Form 4 ↗ same day · 45,003 shares | Form 144 ↗ |
| Nov 10, 2026 | Richard D. Francis Officer | TEVA Teva Pharmaceutical Industries Limited | 250,000 | $10.7M | 10b5-1 | Nov 10, 2026 | Form 4 ↗ 2 days later · 250,000 shares | Form 144 ↗ |
| Nov 9, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 25,000 | $1.1M | — | Nov 9, 2026 | Form 4 ↗ 3 days later · 45,003 shares | Form 144 ↗ |
| Nov 5, 2026 | Mark Sabag Officer, EXECUTIVE VP INTERNATIONAL MAR… | TEVA Teva Pharmaceutical Industries Limited | 46,000 | $1.9M | — | Nov 5, 2026 | Form 4 ↗ 1 day later · 46,000 shares | Form 144 ↗ |
| Nov 4, 2026 | Bergwerk Dov Senior VP General Counsel Corporate Sec… | TEVA Teva Pharmaceutical Industries Limited | 26,260 | $1.1M | — | Nov 4, 2026 | Form 4 ↗ 2 days later · 26,260 shares | Form 144 ↗ |
| Sep 21, 2026 | Brian Savage Officer, CHIEF LEGAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 7,028 | $273.1K | — | Sep 18, 2026 | Form 4 ↗ 1 day later · 7,342 shares | Form 144 ↗ |
| Sep 18, 2026 | Bridger Management, LLC (1) Shareholder | TEVA Teva Pharmaceutical Industries Limited | 367,600 | $14.4M | — | Sep 18, 2026 | — | Form 144 ↗ |
| Aug 17, 2026 | Evan Lippman Officer, EVP BUSINESS DEVELOPMENT | TEVA Teva Pharmaceutical Industries Limited | 18,600 | $680.3K | 10b5-1 | Aug 17, 2026 | Form 4 ↗ 2 days later · 18,600 shares | Form 144 ↗ |
| Aug 3, 2026 | Eric A. Hughes Executive VP Global R&D and Chief Med O… | TEVA Teva Pharmaceutical Industries Limited | 25,578 | $892.1K | 10b5-1 | Aug 3, 2026 | Form 4 ↗ 2 days later · 25,578 shares | Form 144 ↗ |
| Aug 3, 2026 | Jover Placid Executive VP, Chief HR Officer | TEVA Teva Pharmaceutical Industries Limited | 12,827 | $447.4K | 10b5-1 | Aug 3, 2026 | Form 4 ↗ 2 days later · 12,827 shares | Form 144 ↗ |
| Jun 18, 2026 | Matthew Shields Officer, EXECUTIVE VP TEVA GLOBAL OPERA… | TEVA Teva Pharmaceutical Industries Limited | 9,989 | $321.5K | — | Jun 18, 2026 | Form 4 ↗ 4 days later · 9,989 shares | Form 144 ↗ |
| Jun 11, 2026 | Eliyahu Sharon Kalif Officer, EVP CHIEF FINANCIAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 106,563 | $3.6M | 10b5-1 | Jun 11, 2026 | Form 4 ↗ 5 days later · 106,563 shares | Form 144 ↗ |
| Jun 5, 2026 | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 6,153 | $211.4K | 10b5-1 | Jun 5, 2026 | Form 4 ↗ 3 days later · 6,153 shares | Form 144 ↗ |
| Jun 3, 2026 | Matthew Shields Officer, EXECUTIVE VP TEVA GLOBAL OPERA… | TEVA Teva Pharmaceutical Industries Limited | 16,195 | $532.3K | 10b5-1 | Jun 3, 2026 | Form 4 ↗ 1 day later · 16,195 shares | Form 144 ↗ |
| May 14, 2026 | Evan Lippman Officer, EXECUTIVE VP BUSINESS DEVELOPM… | TEVA Teva Pharmaceutical Industries Limited | 41,658 | $1.5M | 10b5-1 | May 14, 2026 | Form 4 ↗ 4 days later · 41,658 shares | Form 144 ↗ |
| May 14, 2026 | Eliyahu Sharon Kalif Officer, EVP CHIEF FINANCIAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 153,251 | $5.5M | 10b5-1 | May 14, 2026 | Form 4 ↗ 4 days later · 153,251 shares | Form 144 ↗ |
| May 5, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 30,000 | $1.1M | — | May 5, 2026 | Form 4 ↗ 2 days later · 30,000 shares | Form 144 ↗ |
| May 4, 2026 | Mark Sabag Officer, EXECUTIVE VP INTERNATIONAL MAR… | TEVA Teva Pharmaceutical Industries Limited | 144,180 | $5.0M | — | May 1, 2026 | Form 4 ↗ same day · 144,180 shares | Form 144 ↗ |
| Apr 30, 2026 | Christine Fox Officer | TEVA Teva Pharmaceutical Industries Limited | 21,258 | $750.6K | — | Apr 30, 2026 | Form 4 ↗ 4 days later · 21,258 shares | Form 144 ↗ |
| Mar 17, 2026 | Mark Sabag Officer, EXECUTIVE VP INTERNATIONAL MAR… | TEVA Teva Pharmaceutical Industries Limited | 62,102 | $1.9M | — | Mar 17, 2026 | Form 4 ↗ 2 days later · 62,102 shares | Form 144 ↗ |
| Mar 5, 2026 | Matthew Shields Officer, EXECUTIVE VP TEVA GLOBAL OPERA… | TEVA Teva Pharmaceutical Industries Limited | 17,295 | $547.7K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 17,295 shares | Form 144 ↗ |
| Mar 5, 2026 | Jover Placid Officer, EXECUTIVE VP CHIEF HUMAN RESOU… | TEVA Teva Pharmaceutical Industries Limited | 14,150 | $448.1K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 14,150 shares | Form 144 ↗ |
| Mar 5, 2026 | Brian Savage Officer, INTERIM CHIEF LEGAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 1,127 | $35.7K | — | Mar 5, 2026 | Form 4 ↗ 4 days later · 1,127 shares | Form 144 ↗ |
| Mar 5, 2026 | Christine Fox Officer, EVP HEAD OF US COMMERCIAL | TEVA Teva Pharmaceutical Industries Limited | 7,924 | $250.9K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 7,924 shares | Form 144 ↗ |
| Mar 5, 2026 | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 20,025 | $634.2K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 20,025 shares | Form 144 ↗ |
| Mar 5, 2026 | Eric A. Hughes Officer, EXECUTIVE VP GLOBAL R AND D CH… | TEVA Teva Pharmaceutical Industries Limited | 9,533 | $301.9K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 9,533 shares | Form 144 ↗ |
| Mar 5, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 17,295 | $547.7K | 10b5-1 | Mar 5, 2026 | Form 4 ↗ 4 days later · 17,295 shares | Form 144 ↗ |
| Mar 4, 2026 | Christine Fox Officer, EVP HEAD OF US COMMERCIAL | TEVA Teva Pharmaceutical Industries Limited | 9,908 | $321.7K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 9,098 shares | Form 144 ↗ |
| Mar 4, 2026 | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 23,393 | $759.4K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 23,393 shares | Form 144 ↗ |
| Mar 4, 2026 | Eric A. Hughes Officer, EXECUTIVE VP GLOBAL R AND D CH… | TEVA Teva Pharmaceutical Industries Limited | 11,277 | $366.1K | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 11,277 shares | Form 144 ↗ |
| Mar 4, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 91,345 | $3.0M | 10b5-1 | Mar 4, 2026 | Form 4 ↗ 2 days later · 91,345 shares | Form 144 ↗ |
| Mar 3, 2026 | Brian Savage Officer, EXECUTIVE VP INTERIM CHIEF LEG… | TEVA Teva Pharmaceutical Industries Limited | 1,274 | $41.2K | — | Mar 3, 2026 | Form 4 ↗ 2 days later · 1,274 shares | Form 144 ↗ |
| Mar 3, 2026 | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 442,935 | $14.3M | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 442,935 shares | Form 144 ↗ |
| Mar 3, 2026 | Eric A. Hughes Officer, EXECUTIVE VP GLOBAL R AND D CH… | TEVA Teva Pharmaceutical Industries Limited | 80,762 | $2.6M | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 80,762 shares | Form 144 ↗ |
| Mar 3, 2026 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 128,985 | $4.2M | 10b5-1 | Mar 3, 2026 | Form 4 ↗ 2 days later · 128,985 shares | Form 144 ↗ |
| Feb 26, 2026 | Eliyahu Sharon Kalif Officer, EVP CHIEF FINANCIAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 345,810 | $11.6M | 10b5-1 | Feb 26, 2026 | Form 4 ↗ 4 days later · 345,810 shares | Form 144 ↗ |
| Feb 18, 2026 amended | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 447,778 | $15.3M | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 15 days later · 442,935 shares | Form 144/A ↗ |
| Feb 18, 2026 | Richard D. Francis Officer, PRESIDENT AND CEO | TEVA Teva Pharmaceutical Industries Limited | 447,778 | $447.8K | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 15 days later · 442,935 shares | Form 144 ↗ |
| Dec 12, 2025 | Bridger Management, LLC (1) Shareholder | TEVA Teva Pharmaceutical Industries Limited | 150,000 | $4.5M | — | Dec 12, 2025 | — | Form 144 ↗ |
| Dec 9, 2025 | Mark Sabag Officer, EXECUTIVE VP INTERNATIONAL MAR… | TEVA Teva Pharmaceutical Industries Limited | 216,892 | $6.2M | — | Dec 9, 2025 | Form 4 ↗ 2 days later · 216,892 shares | Form 144 ↗ |
| Dec 9, 2025 | Richard Daniell Officer, EXECUTIVE VP EUROPEAN COMMERCI… | TEVA Teva Pharmaceutical Industries Limited | 115,468 | $3.3M | — | Dec 9, 2025 | Form 4 ↗ 2 days later · 115,468 shares | Form 144 ↗ |
| Nov 26, 2025 | Bridger Management, LLC (1) Shareholder | TEVA Teva Pharmaceutical Industries Limited | 50,000 | $1.2M | — | Nov 26, 2025 | — | Form 144 ↗ |
| Nov 20, 2025 | Christine Fox Officer, EVP HEAD OF US COMMERCIAL | TEVA Teva Pharmaceutical Industries Limited | 28,229 | $699.5K | 10b5-1 | Nov 20, 2025 | Form 4 ↗ 4 days later · 28,229 shares | Form 144 ↗ |
| Nov 14, 2025 | Christine Fox Officer, EVP HEAD OF US COMMERCIAL | TEVA Teva Pharmaceutical Industries Limited | 30,000 | $753.3K | — | Nov 14, 2025 | Form 4 ↗ 4 days later · 30,000 shares | Form 144 ↗ |
| Nov 6, 2025 amended | Bridger Management, LLC (1) Shareholder | TEVA Teva Pharmaceutical Industries Limited | 200,000 | $4.9M | — | Nov 6, 2025 | — | Form 144/A ↗ |
| Sep 12, 2025 | Bridger Management, LLC (1) Shareholder | TEVA Teva Pharmaceutical Industries Limited | 95,000 | $1.9M | — | Sep 12, 2025 | — | Form 144 ↗ |
| Aug 1, 2025 | Jover Placid Officer, EXECUTIVE VP CHIEF HUMAN RESOU… | TEVA Teva Pharmaceutical Industries Limited | 6,053 | $91.7K | — | Aug 1, 2025 | Form 4 ↗ 4 days later · 6,053 shares | Form 144 ↗ |
| Aug 1, 2025 | Eric A. Hughes Officer, EXECUTIVE VP GLOBAL R AND D CH… | TEVA Teva Pharmaceutical Industries Limited | 52,742 | $799.4K | 10b5-1 | Aug 1, 2025 | Form 4 ↗ 4 days later · 52,742 shares | Form 144 ↗ |
| Jun 12, 2025 | Eliyahu Sharon Kalif Officer, EVP CHIEF FINANCIAL OFFICER | TEVA Teva Pharmaceutical Industries Limited | 55,775 | $952.5K | 10b5-1 | Jun 12, 2025 | Form 4 ↗ 4 days later · 55,775 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 8:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances